Adoption of Lutetium-<sup>177</sup> PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020.
Journal Information
Full Title: Eur J Nucl Med Mol Imaging
Abbreviation: Eur J Nucl Med Mol Imaging
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Nuclear Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Conflict of interestLuka Flegar is a consultant for BK medical. Mrs. Eisenmenger is founder and director of RI Innovation GmbH. All the other authors have no conflicts of interest to declare. Conflict of interest Luka Flegar is a consultant for BK medical. Mrs. Eisenmenger is founder and director of RI Innovation GmbH. All the other authors have no conflicts of interest to declare."
"Funding Open Access funding enabled and organized by Projekt DEAL."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025